Dr. Woodcock is transitioning out of drugs. There
Post# of 148161
(Total Views: 739)
Posted On: 05/20/2022 3:00:09 PM
Dr. Woodcock is transitioning out of drugs. There is an old saying about watching for doorknobs on your way out...................
Excerpts and link below.
FDA commissioner announces new role for Janet Woodcock, downshifting away from drugs
New FDA commissioner Rob Califf told staff in a memo yesterday evening that longtime drug center director Janet Woodcock, who’s now serving as Califf’s principal deputy, would take on more of a role as “a strategic thought partner, with decision-making authorities” at several different offices within FDA. Curiously, the list of offices and centers does not include the Office of New Drugs or the Office of Generic Drugs.
While it’s unclear at the moment whether this new role might expedite Woodcock’s retirement, or if it’s a move she requested, FDA insiders said the announcement effectively means she won’t be returning to or stepping on the toes of anyone serving in the various roles she held previously.
The shift away from regulating drugs follows a historic, almost-four-decade career for Woodcock at the agency, as she served as director of CDER from 1994-2004, and again from 2007-2020, leading the creation and development of the user fee program for drugs.
Most recently she served for about a year as acting FDA commissioner but was never nominated by President Joe Biden to serve as the Senate-confirmed version. Even still, Woodcock has been the face of just about every drug approval decision at the agency since the turn of the century. Since the pandemic began, she’s also moved between the top of the drugs center to the head of therapeutics at Operation Warp Speed, leading the drive for work on Covid-targeted mAbs and antivirals.
https://endpts.com/fda-commissioner-announces...rom-drugs/
Excerpts and link below.
FDA commissioner announces new role for Janet Woodcock, downshifting away from drugs
New FDA commissioner Rob Califf told staff in a memo yesterday evening that longtime drug center director Janet Woodcock, who’s now serving as Califf’s principal deputy, would take on more of a role as “a strategic thought partner, with decision-making authorities” at several different offices within FDA. Curiously, the list of offices and centers does not include the Office of New Drugs or the Office of Generic Drugs.
While it’s unclear at the moment whether this new role might expedite Woodcock’s retirement, or if it’s a move she requested, FDA insiders said the announcement effectively means she won’t be returning to or stepping on the toes of anyone serving in the various roles she held previously.
The shift away from regulating drugs follows a historic, almost-four-decade career for Woodcock at the agency, as she served as director of CDER from 1994-2004, and again from 2007-2020, leading the creation and development of the user fee program for drugs.
Most recently she served for about a year as acting FDA commissioner but was never nominated by President Joe Biden to serve as the Senate-confirmed version. Even still, Woodcock has been the face of just about every drug approval decision at the agency since the turn of the century. Since the pandemic began, she’s also moved between the top of the drugs center to the head of therapeutics at Operation Warp Speed, leading the drive for work on Covid-targeted mAbs and antivirals.
https://endpts.com/fda-commissioner-announces...rom-drugs/
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼